Lilly claims the weight-loss drug reduced the risk of heart failure by 38 per cent in trials 

Trial results show that Eli Lilly's weight-loss drug Zepbound reduces the risk of hospitalisation, death and other outcomes for adults with obesity and a common type of heart failure, the…

WeiterlesenLilly claims the weight-loss drug reduced the risk of heart failure by 38 per cent in trials